Analysts See $-0.36 EPS for Rubius Therapeutics, Inc. (RUBY)

November 11, 2018 - By Harriett Tippett

Analysts expect Rubius Therapeutics, Inc. (NASDAQ:RUBY) to report $-0.36 EPS on November, 30.After having $-3.33 EPS previously, Rubius Therapeutics, Inc.’s analysts see -89.19 % EPS growth. The stock decreased 6.77% or $1.14 during the last trading session, reaching $15.69. About 59,741 shares traded. Rubius Therapeutics, Inc. (NASDAQ:RUBY) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company has market cap of $1.24 billion. The firm is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It currently has negative earnings. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders.

More news for Rubius Therapeutics, Inc. (NASDAQ:RUBY) were recently published by: Seekingalpha.com, which released: “Biotech IPOs on pace for near-record year – WSJ” on October 31, 2018. Globenewswire.com‘s article titled: “Rubius Therapeutics to Announce Third Quarter 2018 Financial Results” and published on November 05, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.